Preeti Agarwal, Fatima Khan, Sameer Gupta, Shalini Bhalla, Ann Thomas, Akshay Anand, Kulranjan Singh, Abhinav Arun Sonkar
{"title":"散发性乳腺癌中激素谱与BRCA1的相关性:303例患者的单一机构经验","authors":"Preeti Agarwal, Fatima Khan, Sameer Gupta, Shalini Bhalla, Ann Thomas, Akshay Anand, Kulranjan Singh, Abhinav Arun Sonkar","doi":"10.1177/2632010X221076379","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Invasive Breast carcinoma-No special type (NST) is the most common breast malignancy accounting for 95% of breast cancers. Study of predictive and prognostic immunohistochemical markers estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2neu) expression are crucial for treatment planning.</p><p><strong>Materials and methods: </strong>In the present study we studied the hormonal profile in 303 sporadic breast cancers and BRCA1 protein expression in these patients along with its clinico-pathological correlation.</p><p><strong>Results: </strong>In our patient population, Triple negative Breast carcinoma (TNBC) (104/303; 34.3%) was the most common luminal subtype followed by Luminal A 74/303; 24.4%), Her2 enriched (65/303; 21.5%), and Luminal B (60/303; 19.8%) respectively. This contrasts with many western studies which commonly report Luminal A being the largest subgroup. BRCA1 protein loss was more prominently seen in TNBC (64/104;61.5%) highlighting the possibility that high grade tumors are more susceptible to some epigenetic modifications leading to higher likelihood of loss of BRCA1 protein.</p><p><strong>Conclusion: </strong>Hence, we conclude that like hereditary cases of breast carcinoma with BRCA1 mutation; BRCA1 loss is also more likely in sporadic TNBC cases.</p>","PeriodicalId":53204,"journal":{"name":"Clinical Pathology","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2022-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fa/53/10.1177_2632010X221076379.PMC8851497.pdf","citationCount":"2","resultStr":"{\"title\":\"Co-Relation of Hormonal Profile and BRCA1 in Sporadic Breast Carcinoma: A Single Institutional Experience of 303 Patients.\",\"authors\":\"Preeti Agarwal, Fatima Khan, Sameer Gupta, Shalini Bhalla, Ann Thomas, Akshay Anand, Kulranjan Singh, Abhinav Arun Sonkar\",\"doi\":\"10.1177/2632010X221076379\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Invasive Breast carcinoma-No special type (NST) is the most common breast malignancy accounting for 95% of breast cancers. Study of predictive and prognostic immunohistochemical markers estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2neu) expression are crucial for treatment planning.</p><p><strong>Materials and methods: </strong>In the present study we studied the hormonal profile in 303 sporadic breast cancers and BRCA1 protein expression in these patients along with its clinico-pathological correlation.</p><p><strong>Results: </strong>In our patient population, Triple negative Breast carcinoma (TNBC) (104/303; 34.3%) was the most common luminal subtype followed by Luminal A 74/303; 24.4%), Her2 enriched (65/303; 21.5%), and Luminal B (60/303; 19.8%) respectively. This contrasts with many western studies which commonly report Luminal A being the largest subgroup. BRCA1 protein loss was more prominently seen in TNBC (64/104;61.5%) highlighting the possibility that high grade tumors are more susceptible to some epigenetic modifications leading to higher likelihood of loss of BRCA1 protein.</p><p><strong>Conclusion: </strong>Hence, we conclude that like hereditary cases of breast carcinoma with BRCA1 mutation; BRCA1 loss is also more likely in sporadic TNBC cases.</p>\",\"PeriodicalId\":53204,\"journal\":{\"name\":\"Clinical Pathology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2022-02-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fa/53/10.1177_2632010X221076379.PMC8851497.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/2632010X221076379\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2632010X221076379","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 2
摘要
浸润性乳腺癌-无特殊类型(NST)是最常见的乳腺恶性肿瘤,占乳腺癌的95%。研究预测和预后的免疫组织化学标志物雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2 (Her2neu)的表达对治疗计划至关重要。材料与方法:本研究对303例散发性乳腺癌患者的激素谱、BRCA1蛋白表达及其临床病理相关性进行了研究。结果:在我们的患者群体中,三阴性乳腺癌(TNBC) (104/303;34.3%)是最常见的luminal亚型,其次是luminal A 74/303;24.4%), Her2富集(65/303;21.5%), Luminal B (60/303;分别为19.8%)。这与许多西方研究形成对比,这些研究通常报告Luminal A是最大的亚群。BRCA1蛋白丢失在TNBC中更为明显(64/104;61.5%),这表明高级别肿瘤更容易受到一些表观遗传修饰的影响,从而导致BRCA1蛋白丢失的可能性更高。结论:BRCA1基因突变的遗传性乳腺癌病例;BRCA1基因缺失也更可能发生在散发性TNBC病例中。
Co-Relation of Hormonal Profile and BRCA1 in Sporadic Breast Carcinoma: A Single Institutional Experience of 303 Patients.
Introduction: Invasive Breast carcinoma-No special type (NST) is the most common breast malignancy accounting for 95% of breast cancers. Study of predictive and prognostic immunohistochemical markers estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2neu) expression are crucial for treatment planning.
Materials and methods: In the present study we studied the hormonal profile in 303 sporadic breast cancers and BRCA1 protein expression in these patients along with its clinico-pathological correlation.
Results: In our patient population, Triple negative Breast carcinoma (TNBC) (104/303; 34.3%) was the most common luminal subtype followed by Luminal A 74/303; 24.4%), Her2 enriched (65/303; 21.5%), and Luminal B (60/303; 19.8%) respectively. This contrasts with many western studies which commonly report Luminal A being the largest subgroup. BRCA1 protein loss was more prominently seen in TNBC (64/104;61.5%) highlighting the possibility that high grade tumors are more susceptible to some epigenetic modifications leading to higher likelihood of loss of BRCA1 protein.
Conclusion: Hence, we conclude that like hereditary cases of breast carcinoma with BRCA1 mutation; BRCA1 loss is also more likely in sporadic TNBC cases.